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A series of rare autoimmune disorders that affect the blood vessels, vasculitis is 
chronic and potentially deadly. Anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) comprise three diagnostic forms of this autoimmune 
disorder: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), 
and eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss 
syndrome). The limited resources available to vasculitis researchers have been mostly 
targeted toward treatment and relapse prediction with a small amount of research 
examining genetic and environmental etiologic factors. Therefore, additional research 
is needed to understand the role of gene-environment interactions in AAV etiology. 
This thesis reviews the current body of AAV literature with a focus on candidate 
genes, occupational and environmental exposures, and the hygiene hypothesis. It also 
designs an original survey and study methodology to further investigate these 
  
etiologic factors. A better understanding of AAV etiology will lead to prevention and 
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Research on vasculitides, a rare group of autoimmune disorders, has increased 
significantly in the last three decades (Pagnoux 2016, Koldingsnes and Nossent 
2008). The label vasculitides encompasses more than 15 different types of vasculitis 
(Koldingsnes and Nossent 2008), diseases characterized by an overactive immune 
response that causes inflammation and subsequent swelling in blood vessel walls. 
Vasculitides are further categorized by the size of the blood vessels affected by the 
immune response and then by their pathology. Small-vessel vasculitides 
predominantly affect capillaries, venules, and arterioles and include two main 
classifications: anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides 
and non-ANCA small-vessel vasculitides (Calatroni et al. 2017). This paper focuses 
on ANCA-associated vasculitides (AAV).  
 Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), 
and eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), the three 
diseases categorized as AAV, occur when B cells produce ANCA. These ANCA 
induce neutrophils to excrete proinflammatory cytokines, which in turn prime the 
neutrophils to bind to endothelial cells in blood vessel walls, causing inflammation 






This group of vasculitides is rare; studies have estimated a worldwide 
incidence of AAV ranging from 2 to 20 cases per million people per year and a 
worldwide prevalence of 23 to 184 cases per million people (Berti et al. 2017, 
Pagnoux 2016). These large ranges can be attributed to the difficulty of studying 
AAV as well as the influence of geographic patterns and AAV type. European studies 
estimate an incidence of 10–20 cases per million people per year (Chen and 
Kallenberg 2010), while a smaller-scale study in Olmsted County, Minnesota found 
an incidence of 33 cases per million per year with individual annual incidence rates of 
13 cases per million, 16 cases per million, and 4 cases per million for GPA, MPA, 
and EGPA respectively (Berti et al. 2017). Furthermore, though these diseases usually 
manifest between ages 50 and 70 (Chen and Kallenberg 2010, Pagnoux 2016), onset 
can happen at any age. AAV incidence in children has been estimated at between 0.5 
and 6.39 cases per million people per year (Calatroni et al. 2017). Current AAV 
incidence rates are higher than those of past decades, but this increase may be 
attributed to increased awareness and a better understanding of the diseases following 
the discovery of ANCA in 1985 (Koldingsnes and Nossent 2008). 
Patient Demographics 
While autoimmune disorders are more common in women (Ngo et al. 2014), 
AAV is distributed fairly evenly between the sexes, though some studies found 
greater incidence in men (Chen and Kallenberg 2010, Watts et al. 2015), and a study 
from China found an increased incidence in women (Chen et al. 2008). AAV also 





to have AAV when compared with African Americans (Koldingsnes and Nossent 
2008). However, while a Chicago study evaluating AAV severity found similar 
numbers of cases for white and Hispanic patients, Hispanic patients had more damage 
and higher levels of disease activity at the time of diagnosis (Sreih et al. 2015). This 
difference may be attributable to health care availability, as language barriers and 
health care costs often prevent Hispanic Americans from seeking early treatment 
(Weinick et al. 2004).  
Disease Pathology 
Presentation 
Each type of AAV presents slightly differently. Though joint pain, rashes, 
respiratory problems, neuropathy, and organ involvement may be hallmarks of any of 
the three, specific symptoms may be more likely depending on AAV type. MPA is 
often accompanied by renal disease, musculoskeletal problems, skin reactions, 
respiratory effects, and gastrointestinal involvement. GPA often first presents as sinus 
or ENT issues and constitutional symptoms and is then followed by renal, respiratory, 
musculoskeletal, and/or skin problems. Finally, EGPA has been linked to asthma and 
often presents with sinusitis, nasal polyps, lung infiltrates, and skin lesions (Calatroni 
et al. 2017). 
Mechanisms 
Despite some differences in manifestation, AAV are often studied together 
because of their similar pathology. AAV is not fully understood; many treatments are 





understanding of the mechanisms of action or the future implications of these 
treatments. However, the presence of ANCA, which was historically considered a 
diagnostic marker of AAV, is now understood to play a pathogenic role in AAV 
development. An unknown triggering event induces the production of ANCA, which 
in turn prime neutrophils and monocytes to begin an immunoresponse, including 
inflammation and vascular necrosis. Underregulated B and T cells incorrectly 
continue the immunoresponse, which further damages blood vessels and significantly 
reduces the oxygen flow to organs (Jarrot and Kaplanski 2016).  
Although ANCA play similar roles in the overactive immune response, there 
are two main forms of these autoantibodies: ANCA with cytoplasmic 
immunofluorescence patterns (c-ANCA) and ANCA with perinuclear 
immunofluorescence patterns (p-ANCA). C-ANCA normally responds to proteinase 
3 and may therefore be referred to as PR3, while p-ANCA responds to 
myeloperoxidase and is therefore often referred to as MPO. PR3 are detected in 60–
80 percent of GPA cases, while MPO are present in 80–90 percent of MPA cases and 
35–40 percent of EGPA cases (Calatroni et al. 2017). As a result of the importance of 
ANCA in AAV pathogenesis as well as new data from cluster analyses, some 
researchers support a reclassification of AAV by phenotype (by ANCA type and 
organ involvement) rather than by symptom (GPA vs. MPA vs. EGPA) (Watts et al. 
2015).  
Relapse and Remission  
There are two stages of AAV treatment: remission induction, which lasts 





stages may last longer depending on practitioner discretion. Remission induction 
involves the use of powerful immunosuppressants like rituximab or 
cyclophosphamide, as well as glucocoritcoids (Mahr et al. 2013, Comarmond and 
Cacoub 2014). The maintenance stage of treatment aims to prevent or limit relapses 
in AAV patients. Relapses or “flares” are common in AAV with GPA, in which 50 
percent of cases relapse, having the highest risk of relapse (Comarmond and Cacoub 
2014, Mahr et al., 2013, Walsh et al. 2012). Unfortunately, the reason for the relapse 
or disease flare is usually unknown (Johns Hopkins Vasculitis Center 2018). 
Therefore, maintenance treatment using immunosuppressant drugs such as 




Geographic Patterns  
Studies have shown that different ANCA types and AAV diagnoses vary in 
prevalence by region. MPO-ANCA is significantly more prevalent in southern 
Europe, Asia, and some parts of the Pacific, but PR3-ANCA is more prevalent in 
North American and northwestern Europe (Renauer et al. 2016). Accordingly, there is 
a higher incidence of MPA in southern Europe and Asia and a higher incidence of 
GPA in northern Europe and Australia (Berti et al. 2017). These differences have 
been interpreted as support for both genetic and environmental etiologic factors; some 





backgrounds, while others claim that environmental triggers could be distributed 
similarly to disease cases (Chen and Kallenberg 2010). 
Candidate Genes 
Candidate genes for AAV differ by study; however, the histocompatibility 
complex HLA, which is implicated in other autoimmune disorders, is consistently 
identified as a potential genetic factor for AAV (Pagnoux 2016, Calatroni et al. 2017). 
A 2007 review study compared potential genetic polymorphisms across multiple 
vasculitis types, but found that most polymorphisms either had not been studied in 
AAV, or that no association had been found (Brogan 2007).  
Evidence for Gene-Environment Interaction 
Despite these genetic factors, AAV is not directly heritable. Although a family 
may have multiple autoimmune disorders, a Swedish study found that close relatives 
of GPA patients have a relative risk of disease of only 1.56, which, given the low 
prevalence of disease, is a fairly small risk (Knight et al. 2008). To the author’s 
knowledge, there are no twin studies on AAV, though one twin case report in Italy 
found two male, monozygotic twin children developed renal limited AAV within 
three years of one another, which the authors took as support for a genetic cause of 
AAV (Giani et al. 2002).  
Geographic AAV patterns, genetic studies, and limited familial clustering of 
AAV highlight potential genetic components of AAV etiology. However, while 
studies have identified multiple candidate genes, no single definitive genetic marker 





inheritance that may rely on gene-environment interactions (Knight et al. 2008). 
Despite evidence for the role of environmental exposures in AAV etiology, the 
interaction between genetic predisposition and environmental triggers is not well 
understood (Renauer et al. 2016). Therefore, as explained by Watts et al. 2015, 
identifying environmental triggers of AAV is necessary for developing etiologic 
solutions based on gene-environment interactions (Watts et al. 2015). 
Potential Environmental Etiology 
Inhaled Irritants 
The respiratory tract involvement in AAV led researchers to hypothesize that 
inhaled irritants from air pollution or occupational exposures may contribute to the 
causal pathway of this group of vasculitides (Koldingsnes and Nossent 2008). Most 
studies evaluating the effects of inhaled irritants on AAV development highlight the 
potential causal role of silica, a mineral found in soil, sand, and rock. Although the 
exact mechanisms of action for silica dust are not fully understood, researchers 
hypothesize that silica’s ability to stimulate lymphocytes, monocytes, and 
macrophages, as well as neutrophil-mediated immune response may trigger ANCA 
activation (Brogan 2007, Chen and Kallenberg 2010).  
Studies have identified construction work (Brogan 2007), farming, mill and 
textile work (Chen and Kallenberg 2010), and even being a first responder (Webber et 
al. 2015) as having both a likelihood of silica exposure and an increased risk of AAV 
and other autoimmune disorders. However, although Chen and Kallenberg reported 





most cases associated with silica exposure involve MPO-ANCA, meaning c-ANCA 
may have a different cause (Chen and Kallenberg 2010).  
Medications 
Certain medications have also been implicated in AAV etiology. Studies have 
identified the thyroid medication propylthiouracil (Watts et al. 2015, Calatroni et al. 
2017, Chen and Kallenberg 2010), the blood pressure medication hydralazine, the 
antibiotic minocycline (Watts et al. 2015, Chen and Kallenberg 2010), and anti-
inflammatory/immunosuppressive drugs such as penicillamine (Calatroni et al. 2017, 
Chen and Kallenberg 2010), dapsone (Calatroni et al. 2017) and hydralazine (Chen 
and Kallengberg 2010) as being associated with AAV. However, these drugs treat 
conditions that may already be associated with or even contribute directly to AAV, 
therefore giving the impression that the drugs induced AAV, despite the patient’s 
potential medical predisposition.  
Furthermore, drug-induced AAV has been found to be more mechanistically 
heterogeneous, with increased activity of other, rarer neutrophil antigens besides 
ANCA (Watts et al. 2015). Additionally, some drug-induced AAV has been found to 
subside after stopping use of the drug (Chen and Kallenberg 2010), meaning drug use 
may not contribute significantly to an etiologic solution.  
 Infections 
 
In addition to inhaled pollutants, some cases of AAV are thought to have been 
triggered by bacterial or viral infections (Calatroni et al. 2017, Pagnoux 2016, Watts 
et al. 2015). The most likely culprit suggested by the current body of literature is 





of GPA. S. aureus peptides are homologous with PR3, indicating a potential 
mechanism for the development of PR3-ANCA (Chen and Kallenberg 2010). 
However, like silica dust exposure, S. aureus infection may only contribute to one 
type of AAV, and is unlikely to be present in all cases.  
Chemical Exposures 
 Finally, there is some evidence that exposure to organic solvents may be 
causally linked to AAV. Floreani et al. suggested that exposure to a variety of 
solvents including dry cleaning chemicals, paint thinners, nail polish removers, and 
cleaning supplies is associated with a number of autoimmune disorders including 
systemic vasculitis (Floreani et al. 2016). A Swedish study on GPA occurrence and 
relative risks reported a potential link between organic solvents and GPA (Knight et 
al. 2008). However, exposure to organic solvents is understudied with regard to AAV.  
The Hygiene Hypothesis 
Overview 
 In addition to the various genetic and environmental factors implicated in 
AAV etiologic research, the hygiene hypothesis, popularized in the field of 
immunology, may also help explain the development of this group of diseases. 
Though each iteration of the hygiene hypothesis attempts to explain the recent 
increase of atopic disease, allergy, and autoimmunity in wealthier countries, its 
definition varies slightly by author. Some researchers frame it as a tradeoff between 
infant mortality and allergy, suggesting that lower rates of childhood infections lead 





Others go further, proposing that the reduced exposure to microorganisms and 
antigens impairs the development of an effective immune system and increases later 
responses to potential triggers (Sironi and Clerici 2010, Versini et al. 2015, Liu and 
Murphy 2003). Generally, the hygiene hypothesis states that because high GDP 
countries often have more sanitization and public health infrastructure, exposures to 
pathogenic infections and microbiota have decreased, which in turn leads to 
incomplete development of the immune system. This incomplete development of the 
immune system leaves children in wealthier countries more likely to generate an 
inflammatory response to environmental triggers, thereby producing atopic, allergic, 
and autoimmune disease.  
 In 1989, David Strachan published research demonstrating that lower rates of 
hay fever in British children were associated with having older siblings; he suggested 
this meant that infections and lower standards of hygiene were protective for allergic 
diseases (Strachan 1989). Although Strachan is given credit for coining the hygiene 
hypothesis, other earlier studies already had begun to notice this potential relationship 
between microbial exposure and increased prevalence of chronic inflammatory 
diseases. For example, in 1966, Leibowitz et al. published a study on Israelis with 
multiple sclerosis (MS). They found that MS was positively associated with higher 
levels of sanitation in patients’ childhood homes (Leibowitz et al. 1966). By 1970, 
Greenwood reported lower prevalence of autoimmune disease in Nigeria and 
attributed this to parasitic infections in childhood (Greenwood and Cantab 1968, 





This body of literature aligns with recent studies reporting increases in 
inflammatory diseases (Rook 2012) such as allergies (Strachan 2000), asthma (Okada 
et al. 2010), and autoimmune disorders including inflammatory bowel disease, 
ulcerative colitis, Crohn’s disease, type-1 diabetes, MS (Versini et al. 2015), and 
systemic lupus erythematosus (Mu et al. 2015), particularly in industrialized countries 
like the United States (Brady 2013). Though it is difficult to determine whether 
increased awareness of these diseases on the part of doctors contributed to the rise in 
their diagnoses, it is worth investigating the hygiene hypothesis and its potential 
explanation for immune system development.   
 Despite these historical studies and recent increases in atopic disease, allergy, 
and autoimmunity, Weber et al. warns researchers not to confuse the hygiene 
hypothesis with general cleanliness. They contend that the hypothesis must be 
carefully defined via specific immunological mechanisms (Weber et al. 2015). These 
mechanisms likely include improper immunoregulation attributable to an imbalance 
of helper T cells (Schaub et al. 2006, Okada et al. 2010, Wills-Karp et al. 2001), the 
production of proinflammatory cytokines (Schuijs et al. 2015), reduced function of 
regulatory T cells (Wills-Karp et al. 2001), and limited Toll-like receptor (TLR) 
priming of dendritic cells (Sironi and Clerici 2010). Proponents of the hygiene 
hypothesis say these mechanisms are influenced by viral and bacterial infections, 
environmental exposure to microbes, or a combination of the two (Schaub et al. 
2006). These exposures contribute to the gene-environment interactions at play in the 
hygiene hypothesis (Wills-Karp et al. 2001, Rook 2012, Schaub et al. 2006). Given 





disease, it is unlikely that the increase could be solely due to significant genetic 
changes (Versini et al. 2015). However, it is possible that genetic polymorphisms in 
genes related to the control of infections could, in combination with environmental 
triggers, allow for the development of such diseases (Okada et al. 2010).   
 Normally, microbial exposures like viruses, bacteria, and parasites, in 
combination with exposure variables and genetic variation, elicit a controlled immune 
response. However, if these immune responses are not properly modulated or if 
genetic components predispose individuals to disease, the original microbial exposure 
triggers a cascade effect resulting in allergy, asthma, or autoimmunity (Liu and 
Murphy 2003). One potential contributor to improper immune system regulation is 
the imbalance of helper T cells. There are two types of helper T cells, Th1 and Th2, 
distinguishable by the responses they trigger. Th1 produces proinflammatory 
cytokines like interleukin 2 (IL-2), while Th2 produces interleukin 3 (IL-3) and 
interleukin 4 (IL-4), among others. IL-2 promotes the development of T regulatory 
cells, and the cytokines produced by Th2 lead to the formation of immunoglobin E 
(IgE), both of which are crucial to a responsive immune defense (Okada et al. 2010, 
Schaub et al. 2006).  
However, if there is not a balance between Th1 and Th2 cells, the immune 
response could lead to excessive inflammation and damage. Left unbalanced, IL-2 
from Th1 can trigger organ-specific autoimmune disease (Wills-Karp et al. 2001), 
and IgE from Th2-produced IL-3 and IL-4 can promote hypersensitivity and allergic 
response (Schaub et al. 2006). Therefore, in terms of the hygiene hypothesis, it is 





environmental exposures children will overproduce IgE, resulting in an atopic or 
allergic response (Wills-Karp et al. 2001, Gale 2002). Since the hygiene hypothesis 
was originally applied to atopy and allergy, the Th1/Th2 balance is rarely used to 
explain the increase in autoimmunity. Nevertheless, it stands to reason that if an 
imbalance of Th1 is connected to autoimmunity and babies are born with the Th2 
skew (Wills-Karp 2001, Gale 2002), then an excess of environmental stimulation to 
create Th1 response could shift the Th1/Th2 balance in favor of Th1 and increase the 
likelihood of an autoimmune disorder.  
Still, some researchers contest that using the Th1/Th2 balance as the 
mechanism for the hygiene hypothesis is overly simplistic. Sheikh et al. found no 
inverse relationship between atopy and autoimmunity, and Weiss highlighted the 
unexplained rise in Th1-mediated autoimmune disorders. Both articles dismissed the 
hygiene hypothesis (Sheikh et al. 2003, Weiss 2008). However, Sironi and Clerici use 
the shortcomings in the Th1/Th2 explanation, particularly the fact that Th1 cytokines 
have been found in cases of atopic disease, to argue for the consideration of other 
potential mechanisms (Sironi and Clerici 2010).  
Instead of relying on the Th1/Th2 balance, some proponents of the hygiene 
hypothesis use regulatory T cells (Tregs) and TLR to explain the inflammation in 
atopic, allergic, and autoimmune disease. CD4+ Treg cells produce the anti-
inflammatory cytokine interleukin 10 (IL-10), meaning that Treg cells can provide 
negative feedback to an immune response (Wills-Karp et al. 2001, Sakaguchi et al. 
2009). When activated, the TLR proteins prime dendritic cells, which in turn release 





cord blood from Karelian (ethnic Finns living in Russian) babies born in low income 
families with lower levels of sanitization had more innate TLR responses when 
compared to Finnish babies, thereby suggesting a role for the hygiene hypothesis in 
immunoregulation (Kallionpaa et al. 2014). Reduced inflammation as a result of 
proper immunoregulation would likely clearly point to fewer chronic inflammatory 
diseases such as atopy, allergy, and autoimmunity.  
Nevertheless, in spite of these potential mechanistic explanations for the 
hygiene hypothesis, detractors argue that most of the evidence in favor of the hygiene 
hypothesis is a result of epidemiological studies, and therefore are unable to 
demonstrate causality (Macpherson and Harris 2004). Furthermore, some argue that 
the lungs of children with asthma and atopy-implicated respiratory diseases are 
primed or underdeveloped before birth, potentially as a result of maternal vitamin D 
deficiencies (Weiss 2008). However, as prenatal and maternal exposure are also 
implicated in the hygiene hypothesis (Ege et al. 2006), this research does not rule it 
out.   
Atopy, Allergy, and Autoimmunity 
Given the potential role of the hygiene hypothesis in explaining the 
development of atopic, allergic, and autoimmune disease, many researchers suggest it 
be used to develop immunotherapeutic tools including vaccines and bacterial extracts 
(Schaub et al. 2006, Rook 2012, Okada et al. 2010). However, the largest and most 
important implication of the hygiene hypothesis is its contribution to etiologic 





to understand how direct and indirect exposure factors can induce the mechanistic 
responses explained in the previous section.  
 Exposures related to the hygiene hypothesis are most likely to have a 
protective effect when they occur prenatally or within the first three years of life (von 
Mutius 2010, Schaub et al. 2006). Direct factors that have been associated with the 
development of chronic inflammatory disease include bacterial and parasitic 
infections. Indirect factors include socioeconomic status, chronic exposure to farms, 
daycare attendance, family size and composition, pet ownership, and mode of 
delivery. It is unclear exactly how these direct and indirect factors regulate the 
immune system, but they have been implicated in epidemiological and experimental 
studies and should be examined further. 
 Although bacterial infections are known to cause a defensive immune 
response in humans, studies supporting the hygiene hypothesis suggest childhood 
bacterial infections may also prime the immune system to avoid the disordered 
inflammatory responses found in atopic, allergic, and autoimmune disease. A cohort 
study in Munich found that a higher concentration of endotoxins—molecules 
produced by Gram-negative bacteria—in the home during the first year of a child’s 
life was associated with lower incidence of asthma, atopic sensitization, eczema, and 
hay fever (Weber et al. 2015). A 2002 study including data from Germany, Austria, 
and Switzerland also identified endotoxin exposure as protective, reporting that 
endotoxin levels found in children’s bedding were inversely associated with hay 
fever, atopic asthma, and atopic sensitization (Braun-Fahrlander et al. 2002). The 





been attributed to endotoxin priming of the immune system that limits release of 
proinflammatory cytokines (Braun-Farhlander et al. 2002, Schuijs et al. 2015). 
 Similarly, parasitic infections influence immunoregulation and promote 
tolerance of antigens. While parasitic infections can be deadly, studies suggest that 
early exposure to parasites like helminths can prevent atopic and allergic responses 
later in life. A study in Caracas, Venezuela found that when children were treated 
with anti-helminth medication, they had increased allergic hypersensitivity as 
indicated by a skin prick test and increased allergen-specific IgE antibodies in their 
serum (Lynch et al. 1993). This suggests that, though helminth infection can cause 
intestinal damage, exposure to these parasites can lead to a better-regulated immune 
system. However, the exact mechanism of helminth influence on the immune system 
is not well understood. Helminths are generally thought to affect different levels of 
the immune system to create a modulatory network (Versini et al. 2015, Maizels 
2016). Gale suggests that helminths activate Treg cells and induce the release of IL-10, 
thereby reducing an inflammatory response (Gale 2002).   
 In addition to these microbial infections, indirect factors related to the hygiene 
hypothesis have played a demonstrable role in the development of chronic 
inflammatory diseases. These factors are likely linked to microbial exposure, but the 
mechanisms are not always clear. Like Strachan 1989 and the studies that came 
before, studies on the indirect factors supporting the hygiene hypothesis are often 
epidemiological rather than experimental. Nevertheless, they highlight behaviors, 
lifestyles, and social dynamics that may influence the development of atopic, allergic, 





development can lead to the identification of new mechanisms at play in the hygiene 
hypothesis. Mechanisms that vary widely across differences in these implicated 
factors are more likely to contribute to disease development as defined in the hygiene 
hypothesis (Strachan 2000).  
 As with most health issues, socioeconomic status (SES) likely plays a role in 
the development of chronic inflammatory diseases. However, unlike with other health 
issues, SES has been positively associated with the development of these diseases. 
The hygiene hypothesis explains this by relating increased SES with reduced 
microbial exposure and a correspondingly underregulated immune system. A German 
study conducted after the country’s reunification found that people in what had been 
West Germany were more likely to have bronchial hyperresponsiveness and atopic 
sensitization when compared to people living in the former-East Germany (Nowak et 
al. 1996). More recently, a 2013 study in Brazil used questionnaires, serum IgE 
levels, and skin prick tests to determine reactivity phenotypes for children. The 
authors found that children with more highly educated mothers lived in cleaner 
environments and had lower rates of pathogenic infections. These children were also 
found to have the most reactive phenotype and a higher likelihood of atopy 
(Figueiredo et al. 2013).  
 In addition to lower SES, chronic prenatal and early exposure to farms is 
thought to be protective against the development of atopic and allergic disease. 
Studies have shown that living on a farm as a child is protective against allergic 
rhinitis (Kipelainen et al. 2000), hay fever (von Ehrenstein et al. 2000) and asthma, 





protective effect also applies to children’s prenatal farm exposure due to maternal 
activity during pregnancy (Ege et al. 2006).  
Notably, a recent study comparing asthma risk between Amish and Hutterite 
farm children demonstrates that all farming exposure is not equally protective. Amish 
children live on less industrialized farms and have significantly lower rates of asthma 
when compared with Hutterite children (Stein et al. 2016). This difference means that 
the variation of endotoxin exposure levels due to farming practices and type of 
livestock is likely the direct factor determining the effects of farm exposure (Schuijs 
et al. 2015, Stein et al. 2016, Ege et al. 2006, von Ehrenstein et al. 2000, Remes et al. 
2003).  
 The effects of family size and composition can be traced back to the 
Strachan’s work beginning the hygiene hypothesis (Strachan 1989). Since then, 
studies have continued to demonstrate the protective effects of older siblings in the 
development of atopic and allergic disease (Strachan 1995, Strachan et al. 1996, 
Bodner et al. 1998). Additionally, it has been suggested that this protective sibling 
effect may be more pronounced when the father also has atopic disease (Mattes et al. 
1998). There is also some evidence that day care attendance within the first six 
months of life can reduce the risk of developing asthma, though the underlying 
mechanisms for this are likely similar to those for family size and composition (Ball 
et al. 2000). 
 Like family size and composition, pet ownership in early life can also affect 
the development of atopic and allergic disease. A recent meta-analysis of studies on 





dog ownership in early childhood was protective (Pelucchi et al. 2013). These results 
echoed a 1999 experimental study on allergic rhinitis, asthma, and allergy, though the 
1999 study also found a slight protective effect for cat ownership (Hesselmar et al. 
1999). 
 Finally, in addition to the above social and behavioral factors contributing to 
the development of chronic inflammatory disease, mode of delivery may also have 
significant effects on the immune system. Neu and Rushing report that the increase of 
autoimmune and allergic diseases in the United States parallel the increase in 
caesarean sections (C-sections). They suggest that mode of birth—C-section vs. 
vaginal—affects which microbes colonize the gut, which in turn can affect the 
development of the immune system. Although gut microbiomes usually become more 
uniform after the first year of life regardless of mode of birth, the emphasis of the 
hygiene hypothesis on exposures during or before the first year of life qualifies mode 
of birth as a factor of interest (Neu and Rushing 2011). However, additional studies 
are required to better define the interplay between mode of birth and the hygiene 
hypothesis.   
AAV in the Context of the Hygiene Hypothesis  
 Although some hygiene hypothesis research acknowledges the potential role 
of early microbial exposures and immune system modulation in the development of 
autoimmune diseases, AAV have not been evaluated with regard to this hypothesis. 
ANCA were only discovered in 1982, meaning that they are only beginning to be 
understood as a pathologic mechanism (Kallenberg 2011). This recent discovery of 





underrepresentation of AAV in etiologic research. Nevertheless, the disease 
development factors identified in research on the hygiene hypothesis may be 
applicable to AAV. 
 The recent increase in diagnosed autoimmune disorders, though perhaps 
attributable in part to the increased awareness of these diseases, has been associated 
with the hygiene hypothesis (Versini et al. 2015, Brady 2013). Therefore, it is 
plausible that this hypothesis could also play a role in the development of AAV. 
Beginning with the Th1/Th2 mechanism implicated in some hygiene hypothesis 
research, AAV as an autoimmune disorder would likely fall on the Th1-skewed side 
of the spectrum. External exposures like bacteria, viruses, and other microbes that can 
trigger a Th1 response may be implicated, either in priming the immune system for a 
more measured response or in causing AAV by triggering an overactive response (Liu 
and Murphy 2003, Johnson et al. 2003). As in the above explanation of the Th1/Th2 
balance, there is contradictory information that calls into question the applicability of 
this potential mechanism. Additionally, if the hygiene hypothesis relies heavily on a 
Th2 skew, as suggested by some studies, organ-specific Th1-mediated autoimmune 
disorders similar to AAV may not be pertinent (Wills-Karp et al. 2001, Weiss 2008).  
 However, because there are some similarities between asthma and bronchial 
hyperreactivity-related disease and AAV, it is possible that the hygiene hypothesis’ 
relevance to asthma development provides enough of a connection to implicate the 
hypothesis in AAV etiologic research. As explained in the environmental etiology 
section above, inhaled irritants are thought to play a role in AAV etiology. As asthma 





in etiologic factors. Liu and Murphy state that childhood autoimmune disorders could 
have similar causes as asthma (Liu and Murphy 2003), but because AAV tends to 
present in 50- to 70-year-old adults, this relationship could be less applicable to AAV 
generally. Nevertheless, this potential relationship between asthma and AAV 
development may be relevant for EGPA specifically, given that EGPA is more likely 
to develop in patients with asthma (Calatroni et al. 2017). Furthermore, the 
eosinophils found in EGPA patients may align more with a Th2 immune response 
(Liu and Murphy 2003), meaning that EGPA could be implicated in the Th2 skew 
found in hygiene hypothesis literature.  
 Another possible link between the hygiene hypothesis and AAV development 
is the geographic patterns found for each. A 2010 review article reported north-south 
and west-east disease gradients that aligned with the hygiene hypothesis. In North 
America, Europe, and China, allergic and autoimmune diseases were more prevalent 
in the north, while infectious diseases were more prevalent in the south. In Europe, 
there was also a higher prevalence of autoimmune disease in the west and a higher 
prevalence of infectious disease in the east (Okada et al. 2010). Notably, similar 
gradients are found for AAV. As explained in the genetic etiology section above, 
MPO-ANCA is more prevalent in southern Europe, while PR3-ANCA is more 
prevalent in northwest Europe. While, these patterns have mostly been attributed to 
genetics, it is possible that environmental factors could be affecting gene expression. 
Taken as support of the hygiene hypothesis, these gradients could imply an 





association between PR3-ANCA-associated vasculitis (GPA) and a lack of immune 
system priming. 
 As a result of the limited information on AAV etiology, it is difficult to gauge 
the relevance of the hygiene hypothesis to the development of these diseases. Future 
studies are required to further examine this potential relationship. In addition to 
identifying any associations between hygiene hypothesis factors and AAV 
development, these studies should focus on examining the timing of the exposure to 
these factors. Infections have been shown to trigger autoimmune disorders, so the 
theory of immunoregulation by these same infections is only plausible if the timing of 











Although the etiology of vasculitis is presumed to have both genetic and 
environmental components, further research is needed to clarify this interaction. The 
goal of this study is to address the research question: Which environmental triggers 
could make genetically predisposed individuals more susceptible to ANCA-
associated vasculitis?  
Study Design 
This study will be a matched case-control design in which there are two 
controls for each case. Cases have a doctor’s diagnosis of AAV (GPA, MPA, EGPA, 
or an unspecified AAV), and controls are the AAV-free biological siblings and first-
cousins of cases. Retrospective data will be collected via a 45- to 60-minute online 
survey. In keeping with the inclusion criteria of a current National Institute of 
Environmental Health Sciences study on siblings and systemic rheumatic disorders, 
sibling pairs should be full biological siblings who are the same sex and within five 
years of age (National Institute of Environmental Health Sciences 2016). First-cousin 
controls should also be biologically related to cases, of the same sex, and within five 
years of age of cases. Ideally, matched sibling and cousin controls will reduce genetic 
variation and eliminate the need for costly genotyping.  
Participants must have been born in the United States. They also must have 





out the online survey). Given the age distribution of AAV, study participants must be 
at least 18 years of age in order to provide more occupational and environmental 
exposure data and avoid confounding by any factors that may affect earlier disease 
onset.  
Participant Recruitment 
Given the exploratory nature of this study and the lack of comprehensive 
exposure information for cases and controls, it is not possible to conduct sample size 
calculations for this study (Dupont 1988). Since AAV is rare and this study’s 
inclusion criteria are somewhat stringent, the goal is to recruit 500 cases and 1,000 
corresponding controls. In order to increase the power of the study, any cases and 
their corresponding controls in addition to this 500-case goal will also be included. 
Before recruitment of any participants begins, the author will obtain approval from 
the University of Maryland Institutional Review Board (IRB). The author has already 
completed her Collaborative Institutional Training Initiative (CITI) certification for 
social and behavioral research.  
Study recruitment will be conducted in two parts with the potential for a third 
round, depending on physician support of this project. First, cases will be contacted 
through three Facebook support groups: Vasculitis Foundation Discussion Forum, 
ANCA Vasculitis, and Let’s Talk Vasculitis. As of June 2018, approximately 258 
people with vasculitis have expressed interest in participating in the survey (~200 
from Vasculitis Foundation Discussion Forum, ~18 from ANCA Vasculitis, and 40 
from Let’s Talk Vasculitis). However, all interested participants may not meet the 





Ideally more participants would hear about the survey via word-of-mouth. 
Additionally, recruitment could be expanded to other smaller Facebook support 
groups if necessary. Although it is not possible to verify the Facebook-identified 
cases via medical records, all report a doctor’s diagnosis of ANCA-associated 
vasculitis. Since the survey requires a sibling and first-cousin control for each case, it 
would be difficult for potential participants to inaccurately represent their diagnosis 
and identify controls who would support their claim.  
In order to complement the data from self-reported cases, study recruitment 
will also include potential identification through existing cohorts of vasculitis patients 
at the National Institutes of Health’s Vasculitis Translational Research Program 
(VTRP) and Medstar Georgetown University Hospital. In accordance with HIPAA, 
doctors will send letters and the study recruitment flyer directly to patients to 
maintain the privacy of their medical diagnoses. Mail is preferable over email for the 
original recruitment due to the age range of the cohort and the repute of mail from 
these institutions. Recruitment flyers will include the secure study email address so 
that potential participants can immediately get more information, provide informed 
consent, and answer screener questions. Anonymized data from the study will be 
shared with all participating doctors in order to help inform their future research.  
Finally, contacts of the author have provided information on vasculitis 
researchers at The Johns Hopkins University School of Medicine and University of 
Pennsylvania School of Medicine who may be open to assisting with recruitment. If 
identifying cases through Facebook support groups, the VTRP, and Medstar 





author will contact these additional researchers to request support in the recruitment 
process.  
As cases are recruited through the Facebook groups and patient cohorts, those 
interested will be asked to email a secure University of Maryland email address to 
obtain access to the online survey. Upon emailing the study address, participant cases 
will be sent the link to the REDCap survey explained in the following section. The 
email with the survey link will also ask that the participant cases contact their own 
sibling and first-cousin controls. The email will include a flyer that cases can share 
with their potential controls to provide information on the study as well as the study 
contact information. If controls are interested in taking the survey, they can email the 
study address for a survey link. They will be asked to list the name of their relative 
with vasculitis who has already consented to and taken the survey so that the surveys 
can be linked.  
Once the case participant and their controls have taken the survey, all three 
will be entered in a raffle to win a Visa gift card (amount to be determined). The 
raffle will occur at the end of data collection and the winner will be contacted via the 
email they used to take the survey.   
Survey Development 
Topics to Assess 
 Chapter 1 reviewed the current literature on AAV etiology. In the creation of 
the study methodology and development of the survey, the author selected what 





The topics selected for inclusion in this survey (Appendix A) were demographic 
information, disease diagnosis and symptoms, health behaviors and characteristics, 
current occupation and work history, exposure from hobbies and living environment, 
and early childhood exposure. Participants will also have a chance to add their own 
thoughts on the survey and the potential causes of vasculitis.  
 Information on demographics and disease will be used to describe the 
population and further categorize the groups used for analysis. Most of the exposure 
questions are designed to collect information on the topics explored in Chapter 1. 
Questions on occupation, hobby, and home exposure assess potential exposures to 
inhaled irritants and solvents. Early childhood exposure questions will help evaluate 
the validity of the hygiene hypothesis for AAV development. Some of the factors 
implicated in the earlier literature review are not assessed in the survey. Medication 
use and infection were deemed too difficult to accurately assess without undue burden 
on participants. Overall, because this is a pilot study relying on sparse epidemiologic 
research, many of the survey questions are limited in scope. The purpose of the 
survey is to identify areas for future etiologic research. Further information about the 
rationale for each of the 43 questions can be found in Appendix B. 
Sourcing Validated Questions 
 In order to evaluate the potential associations between these exposures and 
characteristics and the development of AAV, the author developed a comprehensive, 
43-question survey with validated questions sourced from established research 
projects (Appendix A). Generic demographic questions were taken from national 





the Behavioral Risk Factor Surveillance System (CDC 2018). Specific exposure 
questions were accessed via the following documented research protocols: American 
Thoracic Society’s Epidemiology Standardization Project (Ferris 1978), the 
Birmingham Vasculitis Activity Score (Birmingham Vasculitis Activity Score, n.d.), 
and the Early Life Exposures Assessment Tool (Walker and Bennett n.d.).  
 These research protocols have been carefully developed and tested. Benjamin 
Ferris, MD developed the Epidemiology Standardization Project to ensure that data 
on respiratory symptoms was collected uniformly (Ferris 1978). The Birmingham 
Vasculitis Activity Score (BVAS) identifies nine categories of vasculitis symptoms 
and lists clinical manifestations of these symptoms under each. Although it is used 
only by medical professionals, BVAS was used in the AAV etiologic survey created 
in this thesis to help participants with vasculitis comprehensively report their 
symptoms. The Early Life Exposures Assessment Tool (ELEAT) was developed by 
University of California, Davis researchers Cheryl Walker, MD and Deborah Bennett, 
PhD using funding from Autism Speaks. ELEAT focuses on prenatal and childhood 
exposures relevant to autism spectrum disorder (ASD), but the questions are more 
widely applicable (Walker and Bennett n.d.).  
After reviewing the aforementioned surveys in full, the author used the 
database PhenX Toolkit (RTI International 2018) to search for additional questions 
on exposures relevant to AAV etiology. Questions found using PhenX Toolkit were 
from the 2001 Parkinson’s Disease, Environment, and Genes (PEG) Study (Ritz 
2001), the 1996 Long Island Breast Cancer Study (NIH 1996), and CDC’s Pregnancy 





AAV-relevant topics were not available from any of these sources, original questions 
were created modeled on the wording of questions from these validated sources.  
Analysis and Expected Results 
Demographics and Disease 
 The analysis of the survey responses will be completed using SAS statistical 
software. Demographic information will be used to calculate descriptive statistics. 
The information provided by all participants in the demographics section and by cases 
in the disease section could be used to further divide analysis. For example, disease 
type (GPA, MPA, EGPA) or severity (BVAS score) could be used to divide cases and 
evaluate associations accordingly (i.e. determining whether an exposure could have 
an effect on disease severity). However, given the small sample size of this study, 
further division of participants would significantly reduce the statistical power.   
 In order to better describe the sample and to prepare for exposure analysis, it 
may be necessary to control for race and education. However, given the geographic 
ranges of AAV and the fact that this study will be based in the United States, it is 
likely that the majority of participants will be white, so controlling for race may not 
be informative. Finally, participant addresses should be geocoded and mapped using 
GIS software (see Appendix B, 13 for more information).  
Environmental Exposures 
 In order to evaluate whether the assessed environmental exposures are 
potential risk factors for the development of AAV, SAS software will be used to 





conditional logistic regression may be used if data demonstrate that more than one 
exposure lead to statistically significant increased odds of developing AAV. While all 
exposures assessed in the survey have been associated with AAV development in the 
existing literature, the author expects significant ORs for occupations associated with 
dust exposure (i.e. construction and landscaping). A significant positive association 
between the diseases assessed in the survey and the development of AAV would be 
useful in identifying exposures that may affect the etiology of both diseases.  
 As with any retrospective study, recall bias and limited temporality are 
limitations for this study. However, by asking specific questions about the timing of 
the vasculitis diagnosis and listing options for the questions to assist participants in 
answering accurately, the author has sought to mitigate these limitations. Finally, 
environmental exposures will be further elucidated by controlling for genetic 
clustering of vasculitis and other autoimmune disorders. Additional information can 
be found in Appendix B.  
Hygiene Hypothesis 
 As with the environmental exposure assessment, hygiene hypothesis data 
should be evaluated using adjusted odds ratios from conditional logistic regression. 
Multiple conditional logistic regression should also be run on related factors such as 
number of siblings and birth order to create a more comprehensive model. However, 
because the hygiene hypothesis has not been applied to AAV, future studies will be 
needed to identify the exposures associated with any factors found to be significant.  
 The principal issue in applying the hygiene hypothesis to AAV etiology is that 





point in the hygiene hypothesis is the difficulty of distinguishing between triggering 
and protective infections. This issue is even more apparent in AAV given the lack of 
information on latency periods. Finally, although the geographic gradients associated 
with the hygiene hypothesis give reason to suspect that GPA may be particularly 
associated with hygiene hypothesis-related exposures, because AAV pathology is not 
well understood, mechanisms to explain this association are not available. Therefore, 
current AAV studies, including this thesis, are limited to epidemiologic methods.  
Conclusion 
 In cases of chronic disease, prevention is often the only way to reduce disease 
prevalence. Understanding the etiology of diseases like ANCA-associated vasculitis 
empowers patients to take precautions and allows medical professionals to give more 
specific advice. The study introduced in this thesis is preliminary; the data collected 
from the proposed survey will only suggest associations and areas for future research. 
Nevertheless, the study is necessary to both AAV prognosis and patient peace-of-
mind. Finally, although the author has previously been skeptical of the idea of a 
vasculitis “cure,” as put forth by the Vasculitis Foundation, determining the etiology 
of AAV will allow for a better understanding of its pathogenesis, which in turn could 







APPENDIX A: AAV Survey for Cases and Controls 
Thank you for participating in this study on the potential triggers for ANCA-
associated vasculitis. Your responses and the responses of your cousins and siblings 
will help us learn more about the potential causes of ANCA-associated vasculitis. By 
comparing your answers to those of your family members, we will hopefully be able 
to identify patterns that tell us more about this disease. Please answer each question 
as honestly and accurately as possible. The survey should take about 45 to 60 
minutes, but may be completed more quickly, depending on your answers. 
 




The following section contains questions that give us more information about you and 
your participation in this study.  
 
1) What is your full name? 
 
2) Please provide an email address at which you can be reached. This will be used to 
follow up with you if necessary and also to award the raffle winner their prize. 
 
3) What is your birthdate?  
 - MM/DD/YYYY 
 
4) What is your sex?  
 - Male 
 - Female 
 - Other  
5)  
5a) Are you a vasculitis patient, a sibling of a vasculitis patient, or a cousin?  
- Patient (Proceed to 5b) 
- Sibling (Proceed to 5c) 
- Cousin (Proceed to 5c) 
 
5b) Which form of vasculitis do you have? (Proceed to 6)  
- Granulomatosis with polyangiitis (GPA/Wegener’s) 
- Microscopic polyangiitis (MPA) 
- Eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss) 
- Other (Please specify) 
 







6) In what country were you born?  
 a) Born in one of the 50 U.S. States or Washington, D.C. 
 b) Born elsewhere 
 
DEMOGRAPHIC INFORMATION 
The following questions ask about different demographic information including your 
race, income, and education level. This information will help us understand more 
about the vasculitis community when compared with those without vasculitis. 
 
7) In what state do you currently live? 
 
8) What is the zip code where you currently live?  
 
9) Are you Hispanic, Latino/a, or of Spanish origin?  
 
10) Which one or more of the following would you say is your race?  
- White 
- Black or African American 
- American Indian or Alaska Native 
- Asian 
▪ Asian Indian 
▪ Chinese 
▪ Filipino 
▪ Japanese  
▪ Korean  
▪ Vietnamese 
▪ Other Asian 
- Pacific Islander 
▪ Native Hawaiian  
▪ Guamanian or Chamorro 
▪ Samoan  
▪ Other Pacific Islander 
  
11) What is the highest grade or year of school you completed?  
- Never attended school or only attended kindergarten 
- Grades 1-8 (Elementary) 
- Grades 9-11 (Some high school) 
- Grade 12 or GED (high school graduate) 
- College 1 yr to 3 yrs (some college or technical school) 
- College 4 yrs or more (college graduate) 
- Other (Please specify) 
 
12) This question is about your combined family income. Household income means 
your income plus the income of your family members that live in and/or contribute to 





- Less than $25,000 
- Less than $35,000 ($25,000 to $34,999.99) 
- Less than $50,000 ($35,000 to $49,999.99) 
- Less than $75,000 ($50,000 to 74,999.99) 
- $75,000 or more     
 
13) Where are your current and previous residences? Please list.  
  - Address (Street, City, State, ZIP code if available, Country)  
▪ Dates lived in location (Year to Year)  
 
VASCULITIS DIAGNOSIS AND SYMPTOMS  
This section of the survey will only be available to those who selected responded 
“Patient” to question 5a. The controls will be sent directly to the Health Behaviors 
and Characteristics section below.  
Now we will ask you some questions about your condition.  
 
14) When were you diagnosed?   
- Month, Year 
 
15) 
15a) Do you have c-ANCA (ex. PR3)?  
- Yes 
- No  
- Don’t know 
 
15b) Do you have p-ANCA (ex. MPO)?  
- Yes  
- No 
- Don’t know  
 
16) Please select the symptoms that you experienced at the time of your diagnosis. 
Please only select the symptoms that occurred before your diagnosis. The symptoms 
are divided into categories, but please select all that apply. 
On the REDCap version of the survey each category currently in bold is left as a title 
and the symptoms are all displayed as a checklist. 
 
General symptoms  
- Muscle pain 
- Joint pain or arthritis  
- Fever  
- Noticeable weight loss 
 
Skin symptoms 
- Infarct (as reported to you by a doctor) 
- Purpura (red and/or purple rash) 





- Gangrene (as reported to you by a doctor) 
- Other skin symptoms (please specify) 
 
Mouth, eye, or genital symptoms 
- Mouth ulcers or sores 
- Genital ulcers or sores 
- Eye bulging 
- Eye swelling or inflammation  
- Conjunctivitis (pink eye) or eyelid inflammation  
- Blurred vision 
- Sudden loss of vision  
- Bleeding or blood clot in your eye 
 
Ear, nose, or throat symptoms 
- Bloody nose/crusts inside the nose/sores in the nose 
- Tenderness or pain in your sinuses  
- Narrowing of your windpipe/trachea or tightness in your throat 
- Hearing loss 
 
Lung symptoms  
- Wheeze 
- Fluid in your lungs (as reported to you by a doctor) 
- Bleeding in your lungs 
- Respiratory failure that required you to use artificial respiration  
 
Cardiovascular symptoms  
- Medical staff unable to find your pulse 
- Heart murmur (as reported to you by a doctor) 
- History of one or more heart attacks 
- Heart failure 
- Other heart problems or symptoms (please specify) 
 
 Abdominal symptoms 
- Abdominal pain  
- Bloody diarrhea  
 
Kidney symptoms 
- Hypertension (high blood pressure) 
- Protein in your urine (as reported to you by a doctor) 
- Blood in your urine (as reported to you by a doctor) 
- Elevated creatinine levels (as reported to you by a doctor)  
 
Nervous system symptoms 
- Headache 
- Meningitis (as reported to you by a doctor)  







- Spinal cord lesion (as reported to you by a doctor) 
- Neuropathy or numbness 
 
17) How long after your initial symptoms did you go to a doctor? 
- ______ months 
 
18) How long after your initial symptoms were you diagnosed? 
- ______ months 
   




20) Have you had any disease flares? 
- Yes 
o Please list when each flare occurred after your initial diagnosis. If you 
can’t remember the exact time of the flare, please provide an estimate. 




HEALTH BEHAVIORS AND CHARACTERISTICS  
The following questions ask about your health and health behaviors. These questions 
cover smoking, allergies, mental health, and illness (other than vasculitis). This 
section starts with question 21. If you are not a vasculitis patient, you’ll have skipped 
questions 14 through 20. 
 
21)  
21a) Have you ever smoked cigarettes?  
- Yes 
- Do you now smoke cigarettes (as of 1 month ago)?  
▪ Yes 
• How many cigarettes do you smoke per day now?  
▪ No 
• If you have stopped smoking cigarettes completely, 
how old were you when you stopped? 
- How old were you when you first started regular cigarette 
smoking? ___ age in years 
- On average over the entire time you smoked, how many cigarettes 
did you smoke per day? 
- Do or did you inhale the cigarette smoke? 







▪ Deeply  
- No 
 
21b) Have you ever smoked a pipe regularly?  
- Yes 
- Do you now smoke a pipe (as of 1 month ago)?  
▪ Yes 
• How much pipe tobacco are you smoking now? 
____ oz per week (a standard pouch of tobacco 
contains 1.5 oz) 
▪ No 
• If you have stopped smoking a pipe completely, 
how old were you when you stopped? 
- How old were you when you started to smoke a pipe regularly?  
___ age in years 
- On average over the entire time you smoked a pipe, how much 
pipe tobacco did you smoke per week? ____ oz per week (a 
standard pouch of tobacco contains 1.5 oz) 
- Do or did you inhale the pipe smoke? 
▪ Not at all 
▪ Slightly 
▪ Moderately 
▪ Deeply  
- No 
 
21c) Have you ever smoked cigars regularly?  
- Yes  
- Do you now smoke cigars (as of 1 month ago)?  
▪ Yes 
• How many cigars do you smoke per week now?  
▪ No 
• If you have stopped smoking cigars completely, 
how old were you when you stopped? 
- How old were you when you first started smoking cigars regularly? 
___ age in years 
- On average over the entire time you smoked cigars, how many 
cigars did you smoke per week? 
- Do or did you inhale the cigar smoke? 
▪ Not at all 
▪ Slightly 
▪ Moderately 
▪ Deeply  
- No 
 






- Do you now smoke cigarillos (as of 1 month ago)?  
▪ Yes 
• How many cigarillos do you smoke per week now?  
▪ No 
• If you have stopped smoking cigarillos completely, 
how old were you when you stopped? 
- How old were you when you first started smoking cigarillos? ___ 
age in years 
- On average over the entire time you smoked, how many cigarillos 
did you smoke per week? 
- Do or did you inhale the cigarillo smoke? 
▪ Not at all 
▪ Slightly 
▪ Moderately 
▪ Deeply  
- No 
 
21e) Have you ever smoked E-cigarettes (also called vaping)?  
- Yes 
- Do you now smoke E-cigarettes (as of 1 month ago)?  
▪ Yes 
• How many times per day do you use your E-
cigarette?  
▪ No 
• If you have stopped smoking E-cigarettes 
completely, how old were you when you stopped? 
- How old were you when you first started smoking E-cigarettes? 
___ age in years 
- On average over the entire time you smoked E-cigarettes, how 
many minutes did you smoke per day? 
- Do or did you inhale the E-cigarette smoke? 
▪ Not at all 
▪ Slightly 
▪ Moderately 
▪ Deeply  
- No 
 
22) Has a doctor, nurse, or other health professional ever told you that you had any of 
the following?  
 22a) Ever told you have asthma? 
- Yes 
- How old were you when you were told you have asthma?  
- If you have vasculitis, were you diagnosed with asthma before you 







▪ I do not have vasculitis.  




22b) Ever told you have a depressive disorder (including depression, major 
depression, dysthymia, or minor depression)? 
- Yes 
- How old were you when you were told you have a depressive 
disorder?  
- If you have vasculitis, were you diagnosed with a depressive 
disorder before you began having vasculitis symptoms?  
▪ Yes 
▪ No 
▪ I do not have vasculitis.  
- No 
22c) Ever told you have an anxiety or stress-related disorder (Obsessive 
Compulsive Disorder, generalized anxiety, PTSD, etc.)?  
- Yes 
- How old were you when you were told you have an anxiety or 
stress-related disorder?  
- If you have vasculitis, were you diagnosed with an anxiety or 




▪ I do not have vasculitis.  
- No 
22d) Ever told you have allergies to the environment? 
- Yes (Select all that apply) 
- Pollen 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Mold spores 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 







• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Dust mites 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Animal dander/fur 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Other (Please specify) 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- No 
22e) Ever told you have allergies to food? 
- Yes 
- Cow’s milk 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Soy 






▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Eggs 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Wheat 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Peanuts 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Tree nuts 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Shellfish 






▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Other (Please specify) 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- No 
22f) Ever told you have allergies to medication? 
- Yes 
- Penicillin 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Sulfa drugs 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Insulin 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 





- X-ray contrast/Iodine 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Other (Please specify) 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- No 
22g) Ever told you have allergies to chemicals? 
- Yes 
- Detergents  
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- Other (please specify) 
▪ How old were you when you were told you have this 
allergy?  
▪ If you have vasculitis, were you diagnosed with this allergy 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have this allergy?  
- No 
22h) Ever told you have a clotting disorder?  
- Yes 
- Clotting Disorder 






▪ If you have vasculitis, were you diagnosed with this 




• I do not have vasculitis. 
- Deep Vein Thrombosis 
▪ How old were you when you were told you had deep vein 
thrombosis?  
▪ If you have vasculitis, were you diagnosed with deep vein 
thrombosis before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
- Pulmonary Embolism  
▪ How old were you when you were told you had a 
pulmonary embolism?  
▪ If you have vasculitis, were you diagnosed with a 




• I do not have vasculitis. 
- Unknown Clotting Disorder  
▪ How old were you when you were told you have an 
unknown clotting disorder?  
▪ If you have vasculitis, were you diagnosed with this 




• I do not have vasculitis. 
- No  
22i) Ever told you have hypertension/high blood pressure 
- Yes 
▪ How old were you when you were first told you had high 
blood pressure?  
▪ If you have vasculitis, were you diagnosed with high blood 
pressure before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
▪ Do you still have high blood pressure?  





22j) Ever told you had a thyroid disorder? (Hypothyroidism, 
Hyperthyroidism, Graves Disease, etc.) 
- Yes 
▪ How old were you when you were told you had a thyroid 
disorder?  
▪ If you have vasculitis, were you diagnosed with a thyroid 
disorder before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
- No 
22k) Ever told you have eczema? 
- Yes  
▪ How old were you when you were first told you had 
eczema?  
▪ If you have vasculitis, were you diagnosed with eczema 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
- No 
22l) Ever told you had hay fever? 
- Yes 
▪ How old were you when you were first told you had hay 
fever?  
▪ If you have vasculitis, were you diagnosed with hay fever 
before you began having vasculitis symptoms?  
• Yes 
• No 
• I do not have vasculitis. 
- No 
22m) Ever told you had an autoimmune disorder other than vasculitis? 
(Including but not limited to lupus, multiple sclerosis, rheumatoid arthritis, 
inflammatory bowel disease, type 1 diabetes mellitus, psoriasis, etc.)  
- Yes (please specify) 
▪ How old were you when you were first told you had this 
autoimmune disorder?  
▪ If you have vasculitis, were you diagnosed with this 




• I do not have vasculitis. 







The following questions ask you about your job history and any exposures you may 
have experienced in the workplace. 
 
23) Which of the following best describes your current occupation? After selecting 
the category, please specify your job title in the provided box. 
Agriculture/Farming 
Construction 
Food Preparation/Food Server/Waiter or Waitress 






Public Safety (Police, Firefighter, Security Guard) 




 Transport equipment operatives/Drivers 
Warehouse/Stockroom 
Work in an office environment 
 Not Employed  
 Other (Please specify) 
 
24) What was your occupation before your current position? After selecting the 
category, please specify your job title in the provided box. 
Agriculture/Farming 
Construction 
Food Preparation/Food Server/Waiter or Waitress 






Public Safety (Police, Firefighter, Security Guard) 




 Transport equipment operatives/Drivers 
Warehouse/Stockroom 
Work in an office environment 





 Other (Please specify) 
 
25) Please select the categories for all occupations you have held.  
Agriculture/Farming 
Construction 
Food Preparation/Food Server/Waiter or Waitress 






Public Safety (Police, Firefighter, Security Guard) 




 Transport equipment operatives/Drivers 
Warehouse/Stockroom 
Work in an office environment 
 Never Employed  
 Other (Please specify) 
 
26) Have you ever worked for a year or more in any dusty job?  
- Yes 
▪ If yes, which industry? (Please specify) 
▪ What year did you begin working in this industry?  
▪ How many years total did you work in this industry?  






27) Have you ever been exposed to gas or chemical fumes in your work?  
-  Yes 
▪ If yes, which industry? (Please specify) 
▪ What year did you begin working in this industry?  
▪ How many years total did you work in this industry?  












- Volatile chemicals or solvents 
- Coal or stone dusts 
- Coal tar/pitch/asphalt 
- Diesel engine exhaust 
- Dyes 
- Formaldehyde  
- Gasoline or gasoline exhaust 
- Paints 
- Pesticides/herbicides (such as weed killer/Roundup, permethrin, chlorpyrifos, 
etc.)  
- Textile fibers/dusts 




The following question asks whether you participate in any of the listed hobbies and 
how often you take part in these hobbies. 
 
29) Have you ever participated for 6 months or longer in any of the following 
hobbies? 
- Hobbies using glues 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you used glues for 
this hobby?  
- Hobbies involving soldering, such as jewelry making or stained glass 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you soldered?  
- Developing photographs  
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Oil painting  
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Woodworking or refinishing furniture 





- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Ceramics or pottery making 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Leather crafting 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Other activities involving the use of chemicals (Please specify) 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 
- On average, about how many hours per month have you participated in 
this hobby? 
- Gardening 
- In what year were you first involved in this hobby? 
- In what year were you last involved? 
▪ Box for year or allow to check “still involved” 




The following questions ask about exposures in or around your home. 
 
30) In the last ten years were there any renovations to your home, such as adding a 
room, putting up or taking down a wall, replacing windows, or refinishing floors?  
- Yes 
o Were these renovations before you began having vasculitis symptoms? 
▪ Yes 
▪ No 
▪ I do not have vasculitis 
- No 
 
31) In the last ten years was any pesticide fogger / fumigator used inside your home?  
- Yes 








▪ I do not have vasculitis 
- No 
  
32) In the last ten years did professionals (exterminators, landscape/ garden service) 
apply any pesticides to kill bugs outside your home?  
- Yes 




▪ I do not have vasculitis 
- No 
 
EARLY CHILDHOOD EXPOSURES 
The following questions ask about your early life as an infant and young child. 
 
33) How were you delivered?  
- Vaginally 
- Cesarean delivery (C-section) 
- Don’t know 
 
34) Were you born early?  
- Yes, I was very premature (born between 23 and 28 weeks of pregnancy) 
- Yes, I was somewhat premature (born between 29 and 36 weeks of 
pregnancy) 
- No, I was not born early (born between 37 and 40+ weeks of pregnancy) 
- Don’t know 
 
35) In your family are you the:  
- First child 
- Second child 
- Third child 
- Other (Please specify) 
 
36) How many siblings (full or half) do you have that lived in the same house as you 
growing up?  
- Total number of siblings: ____ 
- Number of older brothers: ____ 
- Number of younger brothers: ____ 
- Number of older sisters: ____ 
- Number of younger sisters: ____ 
 
37) The next two questions are about the home or homes you lived in during your 









37b) Was this home a farm?  
- Yes 
o What kind of farm? 
▪ Livestock 
o What kind of livestock? (Please specify) 
o During your first three years of life, did you 
have regular contact with the farm animals? 
o Did your mother have regular contact with the 
farm animals while she was pregnant with you?  
▪ Crops 
▪ Livestock and crops 
o What kind of livestock? (Please specify) 
o During your first three years of life, did you 
have regular contact with the farm animals? 
o Did your mother have regular contact with the 
farm animals while she was pregnant with you?  
- No 
 
38) Did your family have a dog, cat, or bird living in your home from three months 





- Cat + dog 
- Cat + bird 
- Dog + bird 
- Cat + dog + bird 
 




ADDITIONAL INFORMATION  
The following section is the final part of this questionnaire. These questions ask about 
diseases in other family members and give you a chance to offer your own thoughts 
and feedback.  
 
40) Does anyone else in your family have vasculitis?  
In this question, “family” refers to your biological relatives, or those related to you by 
blood. This may include maternal and paternal biological grandparents, birth parents, 





the children of your birth parents’ siblings (your cousins), but does not include 
people who married into your family (ex. in-laws) or someone who was adopted but 
is not genetically related to you.  
- Yes 
- If yes, what is their relationship to you (ex. mother, father, 
grandparent, paternal uncle, maternal uncle, maternal cousin, etc.)? 
- No 
 
41) Does anyone else in your family have an autoimmune disorder other than 
vasculitis (not including allergies)? Again, as in the above question, here “family” 
refers only to people genetically related to you. Autoimmune disorders include 
illnesses such as lupus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel 
disease, type 1 diabetes mellitus, psoriasis, etc.  
- Yes 
- If yes, what is their relationship to you (ex. mother, father, 
grandparent, paternal uncle, maternal uncle, maternal cousin, etc.)? 
- No 
 
42) What do you think caused your/your relative’s vasculitis?  
 
43) Do you have any other comments on your survey responses or suggestions on 





























APPENDIX B: Survey Key 
BACKGROUND  
1) The name of the participant will be used to match the cases to the controls. It will 
be matched using the controls’ responses to question 5c. 
 
2) The email address will allow for follow up should it be necessary. It will also be 
used to contact the participant who wins the raffle prize. Additionally, many potential 
participants have asked whether the results of this study will be made available to 
them. This email address can be used to distribute a plain language guide. 
 
3) The formatting of this question was sourced from NHANES 2005–2006 (CDC 
n.d.). It will be used to calculate participant ages and to ensure that all controls are 
within five years of age of the cases. 
 
4) This question is from BRFSS 2018 (CDC 2018). It will be used to examine the sex 
ratio in the surveyed population, as well as to ensure that all controls are the same sex 
as their matched case. 
 
5) These questions determine whether the participant answering the survey is a case 
or control. The branching patterns for the rest of the survey will be based off of the 
answers to these questions. 5a determines case or control status, 5b follows up with 
cases to ensure that they have AAV and not a different form of vasculitis, and 5c asks 
controls to provide the name of the relative who invited them to the study so that their 
answers can be matched to their case. 
 
6) This question is from NHANES 1999-2000 (CDC n.d.). It is a screener question, as 
one of the inclusion criteria for participation in this study is that participants must 
have been born in the United States.  
 
DEMOGRAPHIC INFORMATION 
7) This question is from BRFSS 2018 (CDC 2018). It will be used to quickly 
determine the distribution of people in the study. It will also be useful in verifying the 
answers to question 13 and will make coding residences easier. 
 
8) This question is from BRFSS 2018 (CDC 2018). It will be used to quickly 
determine the distribution of people in the study. It will also be useful in verifying the 
answers to question 13 and will make coding residences easier. 
 
9) This question is from BRFSS 2018 (CDC 2018). It is separate from the following 
question on race because Hispanic/Latino/a as a category refers to an ethnicity, rather 
than a race. People may identify as Hispanic/Latino/a and also select any of the races 
given in question 10. It will be used to provide demographic information on the 






10) This question is from BRFSS 2018 (CDC 2018). It will be used both to describe 
the surveyed population and, depending on the variation in reported race, to control 
for race when examining potential associations between exposure and AAV 
development. 
 
11) This question is from BRFSS 2018 (CDC 2018). It gives demographic 
information used to better describe the population, and it may be used as a control 
when examining potential associations between exposure and AAV development.  
 
12) This question was adapted from BRFSS 2018 (CDC 2018) with additional 
wording from NHANES 2015-2015 (CDC n.d.). It will be used to describe the 
population and can also be used to determine whether AAV may vary by 
socioeconomic status. Additionally, given the high cost of AAV treatment, the 
income data for cases could be used to begin a commentary on Medicaid for patients 
with AAV.  
 
13) This residence question was found using PhenX Toolkit. It is from the 2001 
Parkinson’s Disease, Environment, and Genes Study (PEG) (Ritz 2001). It will be 
used to geocode participants’ residences to look for clusters. As a result of the date of 
birth information collected in question 3, it may be possible to color code residences 
by age (ex. residence before age 5). This would allow the author to examine location 
while also beginning to consider time as a factor in AAV development.  
 
VASCULITIS DIAGNOSIS AND SYMPTOMS 
14) This question allows the author to establish temporality between diagnosis and 
exposures/illness assessed later in the survey. It can also be used to establish cases’ 
residential location at the time of diagnosis. Additionally, it can be used to evaluate 
whether most of the participants are recently diagnosed, or whether they have had the 
disease for an extended period of time. 
 
15) This question will be used to identify disease phenotype, which may be a more 
accurate way to categorize disease. However, not all patients will know this 
information, so most of the analysis will rely on cases’ self-identified disease type. 
 
16) This list of nine categories and accompanying symptoms has been adapted from 
BVAS (Birmingham Vasculitis Activity Score n.d.). The author used more accessible 
language than the clinical terms used in BVAS. This will allow for the better 
description of the disease and may potentially allow cases’ BVAS scores to be 
calculated, which could add a dimension of disease severity to the analysis.  
 
17) This question, in combination with question 18, can assess whether there is a gap 







18) This question, in combination with question 17, can assess whether there is a gap 
between the report of symptoms to a medical professional and the receipt of a 
diagnosis. 
 
19) This question helps assess the state of the cases’ disease currently. It may also 
inform the author’s assessment of disease severity.  
 
20) This question collects information on the timing of disease flares in order to better 
understand the disease and allow for the association of a flare with a triggering 
exposure.  
 
HEALTH BEHAVIORS AND CHARACTERISTICS 
21) 21a through 21e assess smoking behavior. These questions are based off the 
format established in Ferris 1978 This will allow the author to gather very specific 
information on products used and frequency of smoking and can be used to evaluate a 
potential association between smoking and AAV. 
 
22) This multiple part question collects limited information on the medical history of 
the cases and controls. The format and content of these questions are based on 
BRFSS 2018 (CDC 2018) and ELEAT (Walker and Bennett n.d.). An additional 
question to assess the temporality of these medical issues compared to the vasculitis 
diagnosis of cases has been added. These questions will be used to determine whether 
AAV is associated with any other medical issues. Asthma is included due to similar 
risks from inhaled exposures and its association with EGPA. Depressive and anxiety 
disorders are included because a recent study found that stress disorders were 
associated with the development of autoimmune diseases, including vasculitis (Song 
et al. 2018). Allergies, hay fever, and eczema are included because of the potential 
link between AAV and the hygiene hypothesis. Clotting disorders and hypertension 
are included given the cardiovascular nature of AAV. Thyroid disorders are included 
because of the influence of the thyroid on the immune system. Finally, autoimmune 
disorders are included due to their demonstrated familial clustering.  
 
OCCUPATION 
23) This question asks about current employment. The list of occupations has been 
adapted from ELEAT (Walker and Bennett n.d.) with additions from Ferris 1978. It 
can be used both to look for an association between job category and AAV 
development and to infer potential exposure by job category (ex. construction and 
silica dust). This question is also important because many vasculitis patients go on 
disability or stop working after their diagnosis. The data collected in this question 
may speak to this pattern. 
 
24) This question asks about the job held before current employment. It can be used 
both to look for an association between job category and AAV development and to 
infer potential exposure by job category (ex. construction and silica dust). It is also 





industry, and to identify which industry a participant worked in if they are no longer 
working.  
 
25) This question will all the author to create a general work history. As in questions 
23 and 24, it can be used both to look for an association between job category and 
AAV development and to infer potential exposure by job category (ex. construction 
and silica dust). 
 
26) This question from Ferris 1978 is a crude measure of exposure. Unlike the 
occupation category where exposure must be assumed (ex. silica dust and 
construction), this question allows a more specific reporting of the exposure. The 
author is particularly interested in this question, given the documented association 
between silica dust exposure and AAV development.  
 
27) This question from Ferris 1978 is a crude measure of exposure. Unlike the 
occupation category where exposure must be assumed (ex. silica dust and 
construction), this question allows a more specific reporting of the exposure. Gas and 
chemical fumes are inhaled irritants, and could also be a result of exposure to 
solvents, both of which are implicated in AAV research. 
 
28) This question is adapted from ELEAT (Walker and Bennett n.d.) as another 
general measure of exposure. Notably, this question also asks about daily life in 
addition to work exposures.  
 
HOBBIES 
29) This question was adapted from the Long Island Breast Cancer Study (NIH 
1996). It assesses chemical and physical exposures that occur during hobbies. It also 
assesses the frequency and duration of these potential exposures. Most of the 
exposures from these hobbies would be inhaled. As with the above questions on 
occupation type, exposure must be inferred. However, given the constraints of a 
retrospective study, that is likely the most accurate way to assess these exposures.  
 
OTHER EXPOSURES 
30) This question from ELEAT (Walker and Bennett n.d.) is a proxy for inhaled 
exposures from renovation. The time period is set in the last ten years to reduce recall 
bias. If the participant responds affirmatively, they are also asked about their 
vasculitis status and whether symptoms of their vasculitis (if they have it) developed 
before the renovations. This question on timing establishes basic temporality.  
 
31) This question from ELEAT (Walker and Bennett n.d.) is a proxy for pesticide 
exposure. It can be assumed that individuals exposed to pesticides sprayed inside 
their homes will have been exposed to higher levels of these chemicals. The time 
period is set in the last ten years to reduce recall bias. If the participant responds 
affirmatively, they are also asked about their vasculitis status and whether symptoms 
of their vasculitis (if they have it) developed before the renovations. This question on 






32) This question from ELEAT (Walker and Bennett n.d.) is a proxy for pesticide 
exposure. It can be assumed that individuals exposed to pesticides sprayed outside 
their homes will have been exposed to lower levels of these chemicals. The time 
period is set in the last ten years to reduce recall bias. If the participant responds 
affirmatively, they are also asked about their vasculitis status and whether symptoms 
of their vasculitis (if they have it) developed before the renovations. This question on 
timing establishes basic temporality. 
 
EARLY CHILDHOOD EXPOSURES 
The following questions are all potentially relevant to the hygiene hypothesis.  
33) This question is adapted from CDC’s Pregnancy Risk Assessment Monitoring 
System (CDC 2017). It will be used to determine whether there is an association 
between mode of birth and development of AAV.  
 
34) This is an original question created to assess timing of birth. Like mode of birth in 
question 33, timing of birth is thought to be associated with the development of the 
gut microbiome. Three options for timing of birth in addition to the “Don’t know” 
option are included to distinguish between the premature birth that often requires 
NICU care and premature birth that may just mean more limited development (New 
York State Department of Health 2009).  
 
35) This question was adapted from ELEAT (Walker and Bennett n.d.) and 
establishes birth order. Birth order has been implicated in the hygiene hypothesis as a 
mitigating factor for the development of allergic and atopic disease.  
 
36) This is an original question that relates to question 35. It assesses number and sex 
of older and younger biologic (full or half) siblings that lived in the participants’ 
childhood home. Number and sex of siblings has been implicated in the hygiene 
hypothesis. This question can also be used to calculate total number of siblings. 
 
37) 37a and 37b ask about residence in the first year of life. 37a was adapted from 
ELEAT (Walker and Bennett n.d.) and can be used to assess inhaled exposures, 
including exposures to pesticides. This question does not include parks because parks 
likely use lower concentrations of pesticides (if any). Additionally, living close to a 
park is also potentially a confounder for SES, which is independently associated with 
the development of atopic, allergic, and autoimmune diseases. 37b was adapted from 
the PEG study (Ritz 2001), but additional questions regarding livestock type, contact 
with animals, maternal exposures, and crops were added by the author. These factors 
have been shown to alter the protect effects of the farm on the development of 
allergic disease and asthma. 
 
38) This question is adapted from Ferris 1978 and ELEAT (Walker and Bennett n.d.). 
Exposure to pets, particularly dogs, at a young age has been shown to be protective 






39) This question is adapted from Ferris 1978. Like sibling size, daycare attendance 




40) This question asks participants to identify any blood relatives with vasculitis. This 
will provide information about familial clustering, which can be used as a control to 
further reduce the influence of genetics in this study. However, if a case identifies a 
sibling or parent with vasculitis, this might point to an environmental exposure in or 
around their home and merits further investigation. 
 
41) This question also assesses familial clustering of autoimmune disorders. Like 
question 40, this could be used to control for genetics in order to better isolate 
environmental factors. However, if a case identifies a sibling or parent with an 
autoimmune disorder, this might point to an environmental exposure in or around 
their home and merits further investigation. 
 
42) This question allows participants to add their own thoughts about AAV etiology. 
It could provide new lines of research, and it is also likely to make cases feel more 
respected. 
  
43) This question allows participants to clarify any of their answers and to give 
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